Doptelet (Avatrombopag) is an oral thrombopoietin receptor agonist, primarily used for the treatment of thrombocytopenia in adult patients with chronic liver disease.

How to Use Doptelet (Avatrombopag)

Timing of Administration

Doptelet should be initiated 10–13 days before the scheduled surgery.

Surgery should be performed within 5–8 days after the last dose to ensure the drug exerts its optimal effect.

Administration Method

Doptelet is an oral formulation, with the recommended dosage being once daily taken with meals, for 5 consecutive days.

This administration method can improve the stability of drug absorption and reduce individual variability.

If a dose is missed, it should be taken as soon as possible. However, a double dose should not be taken to make up for the missed one; instead, the regular dosing schedule should be resumed the next day at the original planned time, ensuring the completion of the full 5-day treatment course.

Dose Adjustment of Doptelet (Avatrombopag)

Principles for Dose Determination

The recommended dose of Doptelet is determined solely based on the patient’s platelet count before surgery, and factors such as the patient’s body weight or age do not need to be considered. This method of dose determination simplifies the clinical decision-making process for medication use.

Specific Dosage Regimens

For patients with a platelet count below 40×10⁹/L, the recommended dose is 60 mg (3 tablets) per day for 5 consecutive days.

For patients with a platelet count between 40–50×10⁹/L, the recommended dose is 40 mg (2 tablets) per day, also for 5 consecutive days.

Precautions

Doptelet is only approved as a short-term 5-day treatment regimen for patients with chronic liver disease. Do not attempt to extend the treatment duration to normalize the platelet count.

Overuse may lead to excessive elevation of platelets, increasing the risk of thrombosis.

In case of overdose, close monitoring of platelet count is required, and standard treatment protocols should be followed to manage potential thrombotic complications.

Use of Doptelet (Avatrombopag) in Special Populations

Pregnant Women

Animal studies have shown that avatrombopag may cause harm to the fetus.

Although human data are limited, it is recommended to inform pregnant women of the potential risks of this drug.

Women of childbearing age should confirm their pregnancy status before using the drug and adopt reliable contraceptive measures during treatment.

If pregnancy occurs or is suspected, the doctor should be notified promptly.

Lactating Women

It is not yet clear whether avatrombopag is excreted in human milk, but animal studies have shown that the drug can pass into breast milk.

It is recommended to suspend breastfeeding during treatment and for at least 2 weeks after the last dose.

During this period, milk can be expressed and discarded regularly to maintain lactation function.

Patients with Hepatic Impairment

Chronic liver disease itself does not affect the pharmacokinetics of avatrombopag, so no dose adjustment is needed.

Patients with end-stage liver disease classified as Child-Turcotte-Pugh Class C should use the drug with caution, as this group of patients may face a higher risk of portal vein thrombosis.